JP2018522579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522579A5 JP2018522579A5 JP2018512825A JP2018512825A JP2018522579A5 JP 2018522579 A5 JP2018522579 A5 JP 2018522579A5 JP 2018512825 A JP2018512825 A JP 2018512825A JP 2018512825 A JP2018512825 A JP 2018512825A JP 2018522579 A5 JP2018522579 A5 JP 2018522579A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- supernatant
- cell culture
- level
- vitro cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006228 supernatant Substances 0.000 claims description 122
- 238000000034 method Methods 0.000 claims description 108
- 238000012606 in vitro cell culture Methods 0.000 claims description 92
- 239000003112 inhibitor Substances 0.000 claims description 65
- 230000011664 signaling Effects 0.000 claims description 61
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 32
- 210000003013 erythroid precursor cell Anatomy 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- -1 Bcl-xL Proteins 0.000 claims description 14
- 210000002536 stromal cell Anatomy 0.000 claims description 13
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 12
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims description 10
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 10
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 10
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 10
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims description 10
- 102000003952 Caspase 3 Human genes 0.000 claims description 10
- 108090000397 Caspase 3 Proteins 0.000 claims description 10
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 10
- 102100031785 Endothelial transcription factor GATA-2 Human genes 0.000 claims description 10
- 102100031690 Erythroid transcription factor Human genes 0.000 claims description 10
- 102100035716 Glycophorin-A Human genes 0.000 claims description 10
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 10
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 claims description 10
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 claims description 10
- 101001066265 Homo sapiens Endothelial transcription factor GATA-2 Proteins 0.000 claims description 10
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 claims description 10
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 claims description 10
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 10
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 10
- 101000621061 Homo sapiens Serum paraoxonase/arylesterase 2 Proteins 0.000 claims description 10
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 10
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 10
- 108090000174 Interleukin-10 Proteins 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 10
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 10
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 10
- 102100022824 Serum paraoxonase/arylesterase 2 Human genes 0.000 claims description 10
- 102000000763 Survivin Human genes 0.000 claims description 10
- 108010002687 Survivin Proteins 0.000 claims description 10
- 208000005980 beta thalassemia Diseases 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 9
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 9
- 108090001007 Interleukin-8 Proteins 0.000 claims description 9
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 8
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 8
- 239000003636 conditioned culture medium Substances 0.000 claims description 6
- 102000005606 Activins Human genes 0.000 claims description 5
- 108010059616 Activins Proteins 0.000 claims description 5
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 claims description 5
- 239000000488 activin Substances 0.000 claims description 5
- 108010031102 heme oxygenase-2 Proteins 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 108060004872 MIF Proteins 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 7
- 210000001956 EPC Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 102000034655 MIF Human genes 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021158571A JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164367P | 2015-05-20 | 2015-05-20 | |
| US62/164,367 | 2015-05-20 | ||
| US201662320032P | 2016-04-08 | 2016-04-08 | |
| US62/320,032 | 2016-04-08 | ||
| PCT/US2016/033187 WO2016187378A1 (en) | 2015-05-20 | 2016-05-19 | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158571A Division JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522579A JP2018522579A (ja) | 2018-08-16 |
| JP2018522579A5 true JP2018522579A5 (cg-RX-API-DMAC7.html) | 2019-06-27 |
Family
ID=57320751
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512825A Pending JP2018522579A (ja) | 2015-05-20 | 2016-05-19 | アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 |
| JP2021158571A Pending JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158571A Pending JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10548976B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3298034A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2018522579A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108350057A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2986432A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1252174A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA42160A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016187378A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| WO2016187378A1 (en) | 2015-05-20 | 2016-11-24 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| WO2018089715A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| EP3567096B1 (en) * | 2017-01-06 | 2024-05-29 | Evident Corporation | Cell observation system |
| CA3082146A1 (en) * | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| CA3098679A1 (en) * | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| JP7388679B2 (ja) * | 2019-05-28 | 2023-11-29 | 学校法人 東洋大学 | 熱中症マーカー及びその利用 |
| IL296394A (en) * | 2020-03-20 | 2022-11-01 | Keros Therapeutics Inc | Type ii activin receptor chimeras and methods of using them |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| KR20230017193A (ko) * | 2020-04-28 | 2023-02-03 | 악셀레론 파마 인코포레이티드 | Actrii 단백질 및 후모세혈관 폐 고혈압 치료에서의 용도 |
| MX2022016237A (es) * | 2020-06-23 | 2023-03-08 | Acceleron Pharma Inc | Proteinas actrii para el tratamiento de la hipertension arterial pulmonar (hap). |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| EP4240399A4 (en) * | 2020-11-06 | 2024-10-09 | Acceleron Pharma Inc. | FORMULATIONS WITH ACTRII POLYPEPTIDE VARIANTS |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4523169B2 (ja) * | 1999-02-04 | 2010-08-11 | プルリステム リミテッド | 造血幹細胞および／または前駆細胞を維持および増加するための方法および装置 |
| EP1356075A4 (en) | 2000-10-16 | 2005-04-13 | Compound Therapeutics Inc | PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| ATE472609T1 (de) | 2001-04-26 | 2010-07-15 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| AU2005266875B2 (en) | 2004-07-23 | 2012-07-26 | Acceleron Pharma Inc. | ActRII receptor polypeptides, methods and compositions |
| JP2008520207A (ja) | 2004-11-16 | 2008-06-19 | アヴィディア リサーチ インスティテュート | タンパク質骨格およびその使用 |
| CN105001320A (zh) | 2005-11-23 | 2015-10-28 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| AU2007334333B2 (en) | 2006-12-18 | 2013-05-30 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for increasing red blood cell levels |
| CN101835485B (zh) | 2007-02-01 | 2016-10-26 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| JP5574711B2 (ja) | 2007-02-09 | 2014-08-20 | アクセルロン ファーマ， インコーポレイテッド | 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用 |
| EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| EP2315602A4 (en) | 2008-06-26 | 2011-11-02 | Acceleron Pharma Inc | METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS |
| WO2010019261A1 (en) | 2008-08-14 | 2010-02-18 | Acceleron Pharma Inc. | Use of gdf traps to increase red blood cell levels |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EP2387412A4 (en) | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE ADIPONECTIN MIRROR |
| US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
| BRPI1010704B1 (pt) | 2009-06-12 | 2021-12-14 | Acceleron Pharma Inc | Polipeptídeo recombinante, proteína de fusão recombinante, preparação farmacêutica e uso da mesma |
| CN105535938B (zh) * | 2009-08-13 | 2022-04-26 | 阿塞勒隆制药公司 | Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平 |
| KR20210029836A (ko) | 2009-09-09 | 2021-03-16 | 악셀레론 파마 인코포레이티드 | ＡｃｔＲＩＩｂ 길항제들와 이의 투약 및 용도 |
| ES2869864T3 (es) | 2009-11-03 | 2021-10-26 | Acceleron Pharma Inc | Procedimientos para el tratamiento de la enfermedad del hígado graso |
| JP6267425B2 (ja) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ， インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用 |
| CN107837390A (zh) | 2011-10-17 | 2018-03-27 | 阿塞勒隆制药公司 | 用于治疗无效性红细胞生成的方法和组合物 |
| CN112933223A (zh) | 2012-10-24 | 2021-06-11 | 细胞基因公司 | 用于治疗贫血的方法 |
| CN113604550A (zh) | 2012-10-24 | 2021-11-05 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
| NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| BR112016024319B1 (pt) | 2014-04-18 | 2024-01-23 | Acceleron Pharma Inc | USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME |
| AP2017009674A0 (en) | 2014-06-13 | 2017-01-31 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| KR102640198B1 (ko) | 2015-05-13 | 2024-02-23 | 셀진 코포레이션 | Actrii 리간드 트랩을 사용한 베타-탈라세미아의 치료 |
| WO2016187378A1 (en) | 2015-05-20 | 2016-11-24 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| WO2017091706A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| RS62011B1 (sr) | 2016-07-15 | 2021-07-30 | Acceleron Pharma Inc | Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije |
| RS65735B1 (sr) | 2016-07-27 | 2024-08-30 | Acceleron Pharma Inc | Kompozicije za upotrebu u lečenju mijelofibroze |
| JP7496686B2 (ja) | 2017-06-14 | 2024-06-07 | セルジーン コーポレイション | 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 |
-
2016
- 2016-05-19 WO PCT/US2016/033187 patent/WO2016187378A1/en not_active Ceased
- 2016-05-19 EP EP16797267.8A patent/EP3298034A4/en not_active Withdrawn
- 2016-05-19 HK HK18111575.0A patent/HK1252174A1/zh unknown
- 2016-05-19 CN CN201680042691.9A patent/CN108350057A/zh active Pending
- 2016-05-19 MA MA042160A patent/MA42160A/fr unknown
- 2016-05-19 CA CA2986432A patent/CA2986432A1/en active Pending
- 2016-05-19 JP JP2018512825A patent/JP2018522579A/ja active Pending
- 2016-05-19 EP EP22201847.5A patent/EP4190805A3/en not_active Withdrawn
- 2016-05-19 US US15/574,897 patent/US10548976B2/en not_active Expired - Fee Related
-
2019
- 2019-12-11 US US16/711,039 patent/US20200101157A1/en not_active Abandoned
-
2021
- 2021-09-29 JP JP2021158571A patent/JP2022023072A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522579A5 (cg-RX-API-DMAC7.html) | ||
| US12286477B2 (en) | Anti-TCR antibody molecules and uses thereof | |
| Verdon et al. | Cellular and molecular mechanisms of CD8+ T cell differentiation, dysfunction and exhaustion | |
| Madonna et al. | The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis | |
| US11708392B2 (en) | Peptide conjugates | |
| ES2900233T3 (es) | Moléculas que se unen a CD70 y métodos de uso de las mismas | |
| Acharya et al. | Interleukin-17A promotes CD8+ T cell cytotoxicity to facilitate West Nile virus clearance | |
| Deckers et al. | Innate immune cells in asthma | |
| US20230374133A1 (en) | Anti-tcr antibody molecules and uses thereof | |
| US20180340021A1 (en) | Conditionally active chimeric antigen receptors for modified t-cells | |
| JP7289562B2 (ja) | 抗ｂｃｍａ単一ドメイン抗体及びその適用 | |
| JP2018184428A5 (cg-RX-API-DMAC7.html) | ||
| US11462297B2 (en) | Selective peptide antagonists | |
| US11111288B2 (en) | Conditionally active chimeric antigen receptors for modified t-cells | |
| JP2020501550A5 (cg-RX-API-DMAC7.html) | ||
| KR20240004462A (ko) | Tcr에 결합하는 다기능성 분자 및 이의 용도 | |
| Paroli et al. | The role of interleukin-17 in juvenile idiopathic arthritis: from pathogenesis to treatment | |
| CN120943971A (zh) | 用于刺激自然杀伤细胞的组合物和方法 | |
| Hirahara et al. | Immune cell-epithelial/mesenchymal interaction contributing to allergic airway inflammation associated pathology | |
| Lamers et al. | Brain-specific HIV Nef identified in multiple patients with neurological disease | |
| Le Floc’h et al. | Blocking common γ chain cytokine signaling ameliorates T cell–mediated pathogenesis in disease models | |
| Gavriil et al. | Engineering solutions for mitigation of chimeric antigen receptor T-Cell dysfunction | |
| Tristán-Manzano et al. | Physiological (TCR-like) regulated lentiviral vectors for the generation of improved CAR-T cells | |
| US20240043475A1 (en) | Peptide conjugates | |
| JP2024538064A (ja) | ミクログリア活性化を抑制するための方法 |